That's why I don't trust the Motley Fool. They were recommending Santos at $12 per share. The jester alone is a warning sign.
Here's the Healthscope article published just 12 days ago:
http://www.********.au/2016/10/11/3-reasons-to-buy-healthscope-ltd-shares/